Advancement of artificial intelligence in digital pathology: from exploratory end point to primary end point in non-alcoholic steatohepatitis clinical trials

被引：0

作者：

Tai, Dean ^{[1
]}

Akbary, Kutbuddin ^{[1
]}

Ren, Yayun ^{[1
]}

Chng, Elaine ^{[1
]}

机构：

[1] HistoIndex Pte Ltd, Clin Res, Singapore, Singapore

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

WED-237

引用

页码：S334 / S334

页数：1

共 35 条

[1] Artificial intelligence-based measurement of non-alcoholic steatohepatitis is an accurate tool for clinical trial enrollment and end point assessment
Pulaski, Hanna
Hou, Hypatia
Resnick, Murray
Harrison, Stephen A.
Sanyal, Arun J.
Ratziu, Vlad
Burt, Alastair
Bedossa, Pierre
Montalto, Michael
Wack, Katy
JOURNAL OF HEPATOLOGY, 2024, 80 : S507 - S507
[2] Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Ratziu, Vlad
Hompesch, Marcus
Petitjean, Mathieu
Serdjebi, Cindy
Iyer, Janani S.
Parwani, Anil V.
Tai, Dean
Bugianesi, Elisabetta
Cusi, Kenneth
Friedman, Scott L.
Lawitz, Eric
Romero-Gomez, Manuel
Schuppan, Detlef
Loomba, Rohit
Paradis, Valerie
Behling, Cynthia
Sanyal, Arun J.
JOURNAL OF HEPATOLOGY, 2024, 80 (02) : 335 - 351
[3] "The unbearable lightness" of the primary end point in clinical trials
Marian, A. J.
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (03) : 1403 - 1406
[4] Clinical relevance of an animal model of non-alcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis
Wei, Yishuang
Zhang, Mengnan
Zhang, Jiliang
Teng, Xiao
Yang, Qiang
Leong, Alvin
Ho, Gideon
Lu, Henry
Xu, Deming
JOURNAL OF HEPATOLOGY, 2022, 77 : S679 - S680
[5] Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology
Harrison, Stephen
Pulaski, Hanna
Vitali, Marlena
Manigat, Laryssa
Kaufman, Stephanie
Hou, Hypatia
Madasu, Susan
Hoffman, Sara
Stanford-Moore, Adam
Egger, Robert
Iyer, Janani
Glickman, Jonathan
Resnick, Murray
Patel, Neel
Taylor, Cristin
Mehta, Shraddha
Myers, Robert
Chung, Chuhan
Patterson, Scott
Sejling, Anne-Sophie
Minnich, Anne
Baxi, Vipul
Subramanian, Mani
Sanyal, Arun
Anstee, Quentin
Loomba, Rohit
Ratziu, Vlad
Wack, Katy
JOURNAL OF HEPATOLOGY, 2023, 78 : S32 - S34
[6] GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe
Mol, Peter G. M.
Maciulaitis, Romaldas
Vetter, Thorsten
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 838 - 840
[7] Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials
Florez, Marcus A.
Jaoude, Joseph Abi
Patel, Roshal R.
Kouzy, Ramez
Lin, Timothy A.
De, Brian
Beck, Esther J.
Taniguchi, Cullen M.
Minsky, Bruce D.
Fuller, Clifton D.
Lee, J. Jack
Kupferman, Michael
Raghav, Kanwal P.
Overman, Michael J.
Thomas, Charles R., Jr.
Ludmir, Ethan B.
JAMA NETWORK OPEN, 2023, 6 (05) : E2313819
[8] FINDINGS FROM A NON-ALCOHOLIC STEATOHEPATITIS (NASH) COHORT DEVELOPED VIA ARTIFICIAL INTELLIGENCE IN A LARGE REPRESENTATIVE POPULATION IN THE U.S
Bandaria, Jigar
Boussios, Costas
Donadio, Gregory
Li, Fang
Mortimer, Kathleen M.
Gliklich, Richard
Starzyk, Kathryn
GASTROENTEROLOGY, 2019, 156 (06) : S1261 - S1261
[9] What is the appropriate primary end point for clinical trials for patients with brain metastases?: In response to Drs. Burri and Asher
Regine, WF
Sperduto, W
Scott, CB
Mehta, MP
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (05): : 1394 - 1394
[10] Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice
Robinson, Andrew G.
Booth, Christopher M.
Eisenhauer, Elizabeth A.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2303 - 2308

← 1 2 3 4 →